Equities
  • Price (SEK)25.92
  • Today's Change1.20 / 4.85%
  • Shares traded290.19k
  • 1 Year change-85.72%
  • Beta1.1483
Data delayed at least 15 minutes, as of Feb 13 2026 17:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Surgical Science Sweden AB is a Sweden-based company, which provides with virtual reality simulators for evidence based laparoscopic and endoscopic training. The systems comprise LapSim, EndoSim and TeamSim trainings. Each training combine graphics and cognitive instruction, imply navigation on touch screens and feature tactile feedback technology. The LapSim trainings consist of laparoscopic exercises that range from basic navigation to advanced suturing, the EndoSim endoscopic exercises range from functions of the scope handle and tube, to loop reduction. The TeamSim comprises procedure modules to train in a real world operation room environment and helps to build team communication skills in crisis and routine situations. The training systems are used by medical training centers and institutes worldwide for practice, validation and certification of students, surgeons, and medical doctors.

  • Revenue in SEK (TTM)975.04m
  • Net income in SEK69.83m
  • Incorporated1997
  • Employees328.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
OssDsign AB180.16m-50.99m679.24m32.00--2.19--3.77-0.5493-0.54932.062.800.51090.36726.955,629,938.00-14.46-25.42-16.05-28.5996.2985.57-28.30-82.426.33-13.770.0044--34.5148.59-2.68--24.28--
BioPorto A/S51.88m-123.17m701.20m48.00--12.90--13.51-0.1973-0.19730.0830.07740.41322.554.69962,131.60-98.08-65.22-133.92-88.7463.9064.15-237.40-222.221.71--0.1916--17.076.36-21.15---20.56--
Senzime AB (publ)89.71m-120.62m723.19m50.00--2.08--8.06-0.8672-0.86720.63942.220.2341.735.991,794,120.00-31.47-35.09-34.04-37.5241.868.75-134.46-400.654.30-7.700.0399--63.5554.1811.50--40.12--
Omda AS444.61m-28.34m812.19m260.00--25.4829.271.83-1.51-1.5123.591.630.679326.5921.701,772,075.00-4.33-5.14-5.39-6.6393.6991.09-6.37-10.320.64830.52810.9359--3.4515.80-163.95---15.57--
Nexstim Oyj106.68m-3.00m864.01m40.00--25.53122.808.10-0.042-0.0421.470.44260.85530.56134.66251,616.80-2.40-12.40-4.17-20.7694.3695.09-2.81-16.291.080.78350.6002--20.5521.1432.79--15.13--
C Rad AB442.00m10.40m931.18m110.0091.182.7544.982.110.31040.310413.2510.280.89284.292.404,018,182.002.107.012.999.8151.9546.992.357.122.771.550.02642.44-5.7814.80-81.40-6.08----
ADDvise Group AB (publ)1.62bn4.30m1.04bn615.0019.910.94029.370.64160.08640.08643.441.830.51677.914.962,534,790.000.13993.410.1744.2839.9146.520.27086.060.75621.620.52510.438921.6836.71-13.0485.8552.63--
Sedana Medical AB (publ)197.61m-40.65m1.06bn117.00--1.17--5.37-0.4092-0.40921.999.140.20121.469.472,670,406.00-4.14-4.90-4.34-5.1670.4768.32-20.57-30.263.28-21.900.0045--16.1720.0682.09--26.45--
Paxman AB (publ)295.08m4.92m1.11bn142.00172.312.5844.863.750.27570.275714.2618.380.84863.454.712,810,305.001.370.84261.601.2067.3468.751.610.79664.071.710.02450.0020.4124.30382.5570.92-3.73--
BICO Group AB1.51bn-1.26bn1.17bn586.00--0.6583--0.775-17.83-9.6821.3425.670.32693.303.652,074,793.00-27.41---35.79--36.91---83.83--1.13--0.4174---3.19--88.56------
Genovis AB116.63m21.19m1.18bn36.0055.514.4936.6910.140.32250.32251.783.990.3404----3,644,719.006.1815.626.5717.5690.2888.8618.1625.11----0.21710.00-17.6216.58-46.4828.08-1.42--
Surgical Science Sweden AB975.04m69.83m1.26bn328.0018.060.29348.661.291.371.3719.1184.270.20511.727.093,558,537.001.473.911.554.1866.6168.947.1621.553.44--0.00040.000.139854.17-43.7359.8939.76--
Nordhealth As532.41m-112.83m1.49bn450.00--3.77--2.79-1.52-1.527.199.330.6188--8.101,383,716.00-13.11---14.99--82.95---21.19------0.00--24.03--31.06------
Stille AB552.55m40.41m1.62bn208.0040.002.3318.252.934.504.5062.0977.100.5311.557.663,891,176.003.886.204.557.1152.4547.217.319.481.87--0.0016.2993.2729.47118.4420.5313.88--
Carasent AB (publ)328.93m-18.60m1.69bn196.00--1.9938.305.15-0.268-0.2684.6411.780.3226--7.351,652,936.00-1.82---2.04--84.59---5.65------0.0412--12.27--9.46------
Detection Technology Oyj-1.06tn-1.06tn1.75bn497.00--2.11----------5.34----------8.02--10.04--46.64--7.502.30----61.79-6.044.37-42.04-0.892-13.111.39
Data as of Feb 13 2026. Currency figures normalised to Surgical Science Sweden AB's reporting currency: Swedish Krona SEK

Institutional shareholders

40.65%Per cent of shares held by top holders
HolderShares% Held
Handelsbanken Fonder ABas of 31 Jan 20264.94m9.67%
Capital Research & Management Co. (World Investors)as of 31 Dec 20243.27m6.41%
Fj�rde AP-fondenas of 31 Dec 20243.06m6.00%
Teknik Innovation Norden Fonder ABas of 31 Dec 20242.34m4.58%
Andra AP-fondenas of 31 Dec 20241.89m3.71%
Swedbank Robur Fonder ABas of 31 Dec 20241.82m3.56%
Montanaro Asset Management Ltd.as of 31 May 20241.09m2.14%
Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 31 Jan 2025856.50k1.68%
Atle Investment Services ABas of 30 Jun 2025777.22k1.52%
Cr�dit Mutuel Asset Management SAas of 31 Dec 2024703.66k1.38%
More ▼
Data from 30 Jun 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.